Floatz Rating
BB68/100
Confidence
Indicative
Sponsor
Royal College of Surgeons, Ireland
Modality
Small molecule
Development Phase
Phase 4 / Approved
Status
Active
Evidence ledger · v0.2
Clinical Evidence
Clinical track record: trial progression, reported outcomes, safety signals, and endpoint quality.
74High confidence
Detailed axis rationale is planned and will be published soon.
| Trial | Phase | Status | N | Primary endpoint | Readout |
|---|---|---|---|---|---|
NCT05773183CT.gov Exploring the Relationship Between Androgen Metabolism, Metabolic Disease and Skeletal Muscle Energy Balance in Men | — | Unknown | — | — | — |
NCT03851627CT.gov Effects of Testosterone Undecanoate vs Placebo on Intrahepatic Fat Content in Overweight/Obese Men With T2DM or Prediabetes and Hypogonadism | — | Recruiting | — | — | — |
NCT03256292CT.gov Long-term Lifestyle Change and Testosterone Replacement | — | Completed | — | — | — |
NCT03619330CT.gov Testosterone Replacement Therapy and Liraglutide Effects on Weight Loss in Hypogonadism. | — | Completed | — | — | — |
NCT03792321CT.gov Study on Effects of Testosterone Replacement Therapy in Hypogonadal Type 2 Diabetic Patients" (SETH2) | — | Completed | — | — | — |
NCT02514629CT.gov Testosterone, Metformin, or Both, for Hypogonadism in Obese Males | — | Completed | — | — | — |
NCT01686828CT.gov T-IR- Study to Understand the Effects of Testosterone and Estrogen on the Body's Response to the Hormone Insulin | — | Completed | — | — | — |
NCT01616732CT.gov Testosterone and Weight Loss | — | Completed | — | — | — |
NCT00805207CT.gov Sex Steroids, Sleep, and Metabolic Dysfunction in Women | — | Completed | — | — | — |
NCT00365794CT.gov Effects of Testosterone Gel on Carbohydrate and Lipid Metabolism In Elderly Obese Men | — | Completed | — | — | — |
Show 2 more trialsShow fewer
NCT00983554CT.gov Metabolic Effects of Steroids in Obese Men | — | Unknown | — | — | — |
NCT01123278CT.gov Testosterone Replacement in Metabolic Syndrome and Inflammation | — | Completed | — | — | — |
Competitive Position
Competitive setting: how crowded the indication is, class-level failures, and timing against rivals.
59High confidence
Detailed axis rationale is planned and will be published soon.
Same indication · Obesity Disorder
| Asset | Sponsor | Phase | Rating |
|---|---|---|---|
| Testosterone Undecylate (this asset) | Royal College of Surgeons, Ireland | Approved | BB · 68 |
| vi-0521 | VIVUS LLC | P4 | BBB |
| Tirzepatide | Royal North Shore Hospital | P4 | BBB |
| asc30 | Ascletis Pharma (China) Co., Limited | P2 | BBB |
| Phentermine | Russell McCulloh, MD | P4 | BBB |
| Survodutide | Boehringer Ingelheim | P3 | BBB |
| Deoxycholic Acid | University of California, San Diego | P4 | BBB |
| Efsubaglutide Alfa | The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School | P4 | BBB |
| Cagrilintide | Novo Nordisk A/S | P3 | BBB |
+42 more in the Obesity Disorder cohort
Other indications for Testosterone Undecylate
| Indication | Sponsor | Phase | Rating |
|---|---|---|---|
| Hypogonadotropic Hypogonadism | — | P4 | A · 82 |
| Type 2 Diabetes Mellitus | — | P4 | BBB · 73 |
| Sexual Disorder | — | P3 | BB · 69 |
Scientific Foundation
Strength of the underlying biology: target validation, tractability, modality fit, and how related mechanisms have fared.
NR
Planned for methodology v0.2.
Development Feasibility
How realistically the program can be executed, drawing on modality precedent, enrollment dynamics, and sponsor delivery.
NR
Planned for methodology v0.2.
Commercial Opportunity
Commercial prize: addressable population, unmet need, and the value case for the indication.
NR
Planned for methodology v0.2.
IP & Exclusivity
Exclusivity position, covering patent protection and freedom-to-operate runway.
NR
Planned for methodology v0.2.
Manufacturing & Supply
Manufacturing and supply readiness, driven by modality process and scale-up risk.
NR
Planned for methodology v0.2.
Related assets
Citation
Floatz Terminal. Testosterone Undecylate in Obesity Disorder. Methodology v0.2. Rated under v0.2 effective July 8, 2026. Last refreshed July 8, 2026. Accessed July 14, 2026. https://terminal.floatz.ai/assets/testosterone-undecylate-obesity-disorder
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →